Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Trastuzumab deruxtecan
Related studies linked through entity extraction aliases.
Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan
- Status
- COMPLETED
- Phase
- N/A
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
- Status
- RECRUITING
- Phase
- PHASE2
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
- Status
- RECRUITING
- Phase
- PHASE4
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Status
- SUSPENDED
- Phase
- PHASE1
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
- Status
- COMPLETED
- Phase
- PHASE2
Scalp Cooling in MBC
- Status
- RECRUITING
- Phase
- PHASE2
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE2
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2